Compare Adaptive Biotechnologies Corp (ADPT) vs Freeport-McMoRan Inc (FCX) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

FCX trades at $59.27, down 2.77% on the day, with a bearish technical signal but strong fundamentals including a 10.34% net income margin and consistent earnings beats. Recent news highlights copper demand growth from AI and energy transitions, positioning FCX as a key player. Cash flow trends show improving operational performance, though net cash flow remains negative due to heavy investments.

Outlook is positive with a consensus price target of $71.81, implying 21% upside, supported by robust copper demand and expansion projects. Risks include commodity price volatility and execution challenges. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor debt levels and global economic conditions.